

PRESS RELEASE

FEBRUARY 10, 2026

JEREMIE TROCHU PROPOSED AS NEW BOARD MEMBER OF NANOLOGICA AB (PUBL)

Jeremie Trochu, CEO of the Ardena Group, is proposed as a new member of the board of directors of Nanologica AB. The proposal has been presented by Nanologica's main owner Flerie Invest AB in connection with Nanologica's acquisition of Ardena Södertälje AB. The proposal will be resolved at the Extraordinary General Meeting on March 4.

The proposal to elect Jeremie Trochu to Nanologica's board of directors marks the continued collaboration between Nanologica and Ardena after Nanologica acquired Ardena Södertälje (now Syntagon) from the Ardena Group. The companies primarily intend to collaborate on joint customer projects, as well as on Ardena's future needs for services offered by Syntagon.

Jeremie Trochu holds a Master's degree in Business Administration from EMLyon, France and has extensive knowledge in the life sciences sector and CDMO industry, with 20 years of experience in successfully building and growing companies globally and leading large-scale transformations. Jeremie was previously part of the team that helped transform Catalent from a private equity spin-off to a publicly traded global CDMO and during his tenure there, he built and operated new businesses in both small and large molecule development and analysis markets, as well as leading successful acquisitions and integration of multiple companies.

"The proposal to elect Jeremie Trochu to our board is excellent. Jeremie is a highly competent and driven leader with extensive experience and knowledge in the life science field at large and the CDMO industry specifically. The fact that he wants to get involved as a board member of Nanologica underlines Ardena's continued interest in Syntagon. Jeremie's knowledge and experience will be extremely valuable in our continued development of the Nanologica Group, which now includes Syntagon", comments Nanologica's chairman of the board Gisela Sibton.

The Extraordinary General Meeting will be held on Wednesday, March 4, 2026 at 10.00 a.m. (CET) at Advokatfirman Lindahl's premises at Smålandsgatan 16, Stockholm. Notification of participation must be received by the company no later than Thursday 26 February 2026, at the address Forskargatan 20 G, SE-151 36 Södertälje, Sweden, or via info@nanologica.com.

For further information, please contact:

Johanna Johansson, Director IR, Communications and Marketing
Ph: +46 72 211 21 90 or e-mail: ir@nanologica.com

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long



lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

